3 days ago · Novo Nordisk plans further clinical development of amycretin for obesity and overweight treatment. ... Amycretin (Novo Norisk) led to a reduction in body weight across the …

Jan 24, 2025 · Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults …

Sep 12, 2024 · Early findings from a phase 1 clinical trial first announced by the Danish company Novo Nordisk in March 2024, show that amycretin — an experimental drug they have …

Jan 28, 2025 · With amycretin, Novo Nordisk expects to improve on the efficacy of its blockbuster drug semaglutide, sold under the brand names Ozempic and Wegovy. Semaglutide is a …

Jan 24, 2025 · About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and …

3 days ago · Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.

Jan 24, 2025 · Novo Nordisk reported today that amycretin, an investigational glucagon-like peptide-1 (GLP-1) and amylin receptor agonist, led to significant weight reductions in …

Sep 23, 2024 · In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months. Amycretin targets GLP-1 receptors and a second …

Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection …

3 days ago · Amycretin, a unimolecular glucagon-like peptide-1 (GLP-1) and amylin receptor agonist, showed an estimated body weight loss of 9.7% with a 1.25 mg dose (20 weeks), Novo …